FDA panel rejects Merck’s Arcoxia

Share this article:
An FDA advisory panel voted against the approval of Merck’s Vioxx-successor Arcoxia (etoricoxib) as a treatment for osteoarthritis. The nonbinding vote on the drug was 20-1. The FDA is not required to follow the recommendations of its advisory panels, but usually does. Merck said it expects the FDA will make a final decision on Arcoxia by the end of the month. During a conference call with reporters after the Arcoxia vote, Robert Meyer, director of CDER's Office of Evaluation II, said that the committee was particularly concerned about the cardiovascular safety of the drug. Such risk concerns, he added, could mean that future NSAID or coxib agents could have to show a unique benefit to gain marketing approval. “It seems like [the committee] had concerns that, if there was just another product with the same level of risks of those out there now but no unique benefit, that...didn’t seem to be sufficient reason to approve such a product,” he said.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.